Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-2023 · 1 trial · 1 indication
Count of events
| Arm | Type | Description |
|---|---|---|
| NNC0113-2023 | EXPERIMENTAL | Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo (NNC0113-2023) |
| Name | Type | Description |
|---|---|---|
| NNC0113-2023 | DRUG | Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose. |
| Placebo (NNC0113-2023) | DRUG | Participants will receive NNC0174-0833 matched placebo orally. |
Inclusion Criteria: * Male aged 18 - 45 years (both inclusive) at the time of signing informed consent. * Body mass index between 20.0 kg/m\^2 and 29.9 kg/m\^2 (both inclusive). * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ...
NNC0113-2023 is an investigational small molecule being developed for the treatment of Diabetes Mellitus, Type 2. It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being studied for safety and tolerability in clinical trials.
NNC0113-2023 is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting clinical research to evaluate the drug's potential as a treatment for Type 2 diabetes.
NNC0113-2023 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved for use. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
NNC0113-2023 has one completed Phase 1 clinical trial registered as NCT03617081, titled "First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men." The trial enrolled 40 participants in the United States and was a randomized, double-blind, placebo-controlled study.
NNC0113-2023 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being studied under this identifier in clinical trials for Type 2 diabetes.